Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI. We also review and discuss the available literature. Copyright © 2009 Multimed Inc.
CITATION STYLE
Gaulin, J., Kotb, R., Turcotte, E., Berard, G., Sawan, B., Schmutz, G., & Beauregard, P. (2009). Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer. Current Oncology, 16(5), 84–86. https://doi.org/10.3747/co.v16i5.395
Mendeley helps you to discover research relevant for your work.